Ixabepilone Injection and Enzalutamide: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Enzalutamide
Ixabepilone Injection
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Decreased ixabepilone exposure and efficacy
Interaction Deep Dive
Coadministration of ixabepilone, a CYP3A4 substrate, with a strong CYP3A4 inducer has decreased ixabepilone plasma concentration, which may decrease its efficacy. In a drug interaction study, coadministration of ixabepilone with rifampin, a strong CYP3A4 inducer, decreased ixabepilone AUC by 43% compared to ixabepilone treatment alone. Avoid the coadministration of ixabepilone with strong CYP3A4 inducers. If the coadministration cannot be avoided, gradually increase the ixabepilone dose from 40 to 60 mg/m(2) as tolerated once the patient has been maintained on a strong CYP3A4 inducer. Administer ixabepilone as a 4-hour IV infusion and monitor the patient carefully for adverse reactions. If the strong inducer is discontinued, reduce the ixabepilone dose to that before initiating the strong CYP3A4 inducer1.
Why it happens (mechanism)
Induction of CYP3A4-mediated ixabepilone metabolism
Literature reports
1 report — tap to read
a) Coadministration of ixabepilone with rifampin, a strong CYP3A4 inducer, decreased ixabepilone AUC by 43% compared to ixabepilone treatment alone 1.
Common questions
Can I take Ixabepilone Injection and Enzalutamide together?
Decreased ixabepilone exposure and efficacy Always confirm with your pharmacist or prescriber before making any change.
How serious is the Ixabepilone Injection and Enzalutamide interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Ixabepilone Injection or Enzalutamide need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: IXEMPRA(R) intravenous injection, ixabepilone intravenous injection. R-Pharm US LLC (per FDA), Princeton, NJ, 2022. DailyMed
Keep reading about Enzalutamide
Keep reading about Ixabepilone Injection
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist